SCHEMBL18220147

SCHEMBL18220147

COCCNC(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCCCC4)ccc3c2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.43
GAA P10253 4/20 0.40
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
KMT2A Q03164 5/20 0.39
MEN1 O00255 4/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.38
CSF1R P07333 5/20 0.37
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220149 0.93 APP (0.44) APPGAAKDM4EALDH1A1HPGD
SCHEMBL18220144 0.93 ALDH1A1 (0.46) APPGAAKDM4EALDH1A1HPGD
SCHEMBL23134917 0.90 APP (0.36) APPGAAKDM4EALDH1A1HPGD
SCHEMBL19293974 0.86 MAPT (0.43) APPGAAKDM4EALDH1A1HPGD
SCHEMBL17120663 0.85 APP (0.35) APPGAAKDM4EALDH1A1HPGD
SCHEMBL18220259 0.85 APP (0.35) APPKDM4EALDH1A1KMT2AMEN1
SCHEMBL18219999 0.84 APP (0.48) APPGAAKDM4EALDH1A1HPGD
SCHEMBL17120756 0.83 APP (0.39) APPGAAKDM4EALDH1A1HPGD
SCHEMBL23134918 0.83 APP (0.38) APPGAAKDM4EALDH1A1HPGD
SCHEMBL18220172 0.83 APP (0.42) APPGAAKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-20210369873-A1 COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY Amydis, Inc. 2021-12-02 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885GAA 38/4885KDM4E 4807/4885
US-20210369873-A1 COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY S100B, FABP7, CRYAB APP 4/4885GAA 1799/4885KDM4E 4796/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885GAA 38/4885KDM4E 4807/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885GAA 37/4885KDM4E 4804/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885GAA 37/4885KDM4E 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.